Cargando…

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer

BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Janowski, Einsley-Marie, Kole, Thomas P., Chen, Leonard N., Kim, Joy S., Yung, Thomas M., Collins, Brian Timothy, Suy, Simeng, Lynch, John H., Dritschilo, Anatoly, Collins, Sean P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490223/
https://www.ncbi.nlm.nih.gov/pubmed/26191507
http://dx.doi.org/10.3389/fonc.2015.00151
_version_ 1782379466374250496
author Janowski, Einsley-Marie
Kole, Thomas P.
Chen, Leonard N.
Kim, Joy S.
Yung, Thomas M.
Collins, Brian Timothy
Suy, Simeng
Lynch, John H.
Dritschilo, Anatoly
Collins, Sean P.
author_facet Janowski, Einsley-Marie
Kole, Thomas P.
Chen, Leonard N.
Kim, Joy S.
Yung, Thomas M.
Collins, Brian Timothy
Suy, Simeng
Lynch, John H.
Dritschilo, Anatoly
Collins, Sean P.
author_sort Janowski, Einsley-Marie
collection PubMed
description BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up of 3 years were included in this retrospective review of prospectively collected data. All patients were treated to 35–36.25 Gy in five fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow-up. RESULTS: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk according to the D’Amico classification) at a median age of 69 years (range 48–91) received SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe dysuria bother at 1 month and at 6–12 months, with 9% of patients experiencing a late transient dysuria flare. While a low level of dysuria was seen through the first 2 years of follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA score on multivariate analysis. Frequency and strain significantly correlated with dysuria on stepwise multivariate analysis. CONCLUSION: The rate and severity of dysuria following SBRT is comparable to patients treated with other radiation modalities.
format Online
Article
Text
id pubmed-4490223
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44902232015-07-17 Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer Janowski, Einsley-Marie Kole, Thomas P. Chen, Leonard N. Kim, Joy S. Yung, Thomas M. Collins, Brian Timothy Suy, Simeng Lynch, John H. Dritschilo, Anatoly Collins, Sean P. Front Oncol Oncology BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up of 3 years were included in this retrospective review of prospectively collected data. All patients were treated to 35–36.25 Gy in five fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow-up. RESULTS: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk according to the D’Amico classification) at a median age of 69 years (range 48–91) received SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe dysuria bother at 1 month and at 6–12 months, with 9% of patients experiencing a late transient dysuria flare. While a low level of dysuria was seen through the first 2 years of follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA score on multivariate analysis. Frequency and strain significantly correlated with dysuria on stepwise multivariate analysis. CONCLUSION: The rate and severity of dysuria following SBRT is comparable to patients treated with other radiation modalities. Frontiers Media S.A. 2015-07-03 /pmc/articles/PMC4490223/ /pubmed/26191507 http://dx.doi.org/10.3389/fonc.2015.00151 Text en Copyright © 2015 Janowski, Kole, Chen, Kim, Yung, Collins, Suy, Lynch, Dritschilo and Collins. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Janowski, Einsley-Marie
Kole, Thomas P.
Chen, Leonard N.
Kim, Joy S.
Yung, Thomas M.
Collins, Brian Timothy
Suy, Simeng
Lynch, John H.
Dritschilo, Anatoly
Collins, Sean P.
Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_full Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_fullStr Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_full_unstemmed Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_short Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
title_sort dysuria following stereotactic body radiation therapy for prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490223/
https://www.ncbi.nlm.nih.gov/pubmed/26191507
http://dx.doi.org/10.3389/fonc.2015.00151
work_keys_str_mv AT janowskieinsleymarie dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT kolethomasp dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT chenleonardn dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT kimjoys dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT yungthomasm dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT collinsbriantimothy dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT suysimeng dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT lynchjohnh dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT dritschiloanatoly dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer
AT collinsseanp dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer